Drug intelligence / Profile preview

RJ4348

Development stage: Preclinical
Lead developer: Nanjing Ruijie Pharmaceutical Technology
Modality: Small Molecules

Overview

RJ4348 is a small molecule drug candidate currently under development by Nanjing Ruijie Pharma for the treatment of non-alcoholic steatohepatitis (NASH), also known as metabolic dysfunction-associated steatohepatitis (MASH). As of early 2024, the specific biological target of RJ4348 has not been publicly disclosed by the developer. The compound is part of a broader pipeline at Nanjing Ruijie Pharma focused on small molecule interventions for metabolic and inflammatory conditions.

Beyond the preview

Go deeper on RJ4348.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RJ4348.

Explore the full profile